Melbourne investor briefing presentation

Jul 28, 2026 at 11:56 PM EDT · Issued by Neurizon Therapeutics Limited via ASX

Filed with ASX · Jul 28, 2026 at 11:56 PM EDT

On 6ix: 6ix.com/news/melbourne-investor-briefing-presentation

Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222 Melbourne investor briefing presentation 29 July 2026 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB:...

View Attachment

6ix hasn’t read this filing yet.

Neurizon Therapeutics Limited on 6ix

In the deck

Neurizon Therapeutics — Investor Presentation (July 2026)23 slidesJul 29, 2026

Earlier from Neurizon Therapeutics

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027Jul 16
HEALEY Enrolment Complete - Topline Accelerated to Q2 CY27Jul 16
Neurizon executes long-term supply agreement with ElancoJun 16
HEALEY ALS Trial Surpasses 50% Dosing Ahead of ScheduleJun 11
HEALEY ALS Platform Trial Regimen I expands to 240 participantsMay 27

Later from Neurizon Therapeutics

Appendix 4C & Quarterly UpdateJul 31
Neurizon Enters Strategic R&D Financing FacilityJul 31
Neurizon Completes Initial Drawdown under R&D FacilityAug 10
Elanco representative appointed as Neurizon Board ObserverAug 12
Notification regarding unquoted securities - NUZAug 24

All Neurizon Therapeutics news releases

Follow Neurizon Therapeutics into a list and get an email when it puts out news.

Follow Neurizon Therapeutics